SCHEMBL23835281

SCHEMBL23835281

COC(=O)c1cnc(O)c(F)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
TSHR P16473 2/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 2/20 0.37
ABL1 P00519 1/20 0.37
GLA P06280 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
PDK2 Q15119 1/20 0.36
PDK4 Q16654 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23834897 0.86 MAPT (0.39) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL16965445 0.86 MAPT (0.39) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL31267349 0.86 MAPT (0.39) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL23835458 0.83 GAA (0.41) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL23835101 0.79 GAA (0.35) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL23834844 0.77 MAP2K1 (0.40) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL23835434 0.77 NR3C1 (0.36) MAPTTSHRKDM4EALDH1A1GAA
SCHEMBL28041813 0.77 KDM4E (0.41) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL31923 0.75 MAPT (0.43) MAPTTSHRLMNAKDM4EALDH1A1
SCHEMBL24815466 0.75 MAPT (0.38) MAPTTSHRLMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121421-B1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2026-03-11 EP disclosed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 US disclosed
EP-4121421-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS Novartis AG (CH) 2023-01-25 EP disclosed
CN-115298170-A Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions 诺华股份有限公司 2022-11-04 CN disclosed
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2021-09-30 US disclosed
WO-2021186324-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 MAPT 559/4885TSHR 2251/4885LMNA 2952/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 MAPT 559/4885TSHR 2251/4885LMNA 2952/4885
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 MAPT 577/4885TSHR 2349/4885LMNA 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.